Kris Cameron Wood

Wood

Associate Professor of Pharmacology and Cancer Biology

Appointments and Affiliations

  • Associate Professor of Pharmacology and Cancer Biology
  • Member of the Duke Cancer Institute

Contact Information

  • Email Address: kris.wood@duke.edu
  • Websites:

Education

  • Ph.D. Massachusetts Institute of Technology, 2007
  • B.S. University of Kentucky, Lexington, 2002

Research Interests

More effective anticancer therapeutic strategies, many of which are based on functional genomics. Examples of projects include: a miniaturized screening platform, tools to systematically map the signaling pathways controlling anticancer drug responses, high-throughput computational methods to discover anticancer drug combinations, design of therapeutic strategies to reverse or prevent drug resistance, and systematic credentialing of mutations uncovered through cancer genome sequencing projects.

Courses Taught

  • BIOLOGY 728A: University Program in Genetics and Genomics Biological Solutions Module I
  • CMB 710E: Cell & Molecular Biology Module V
  • CMB 778A: University Program in Genetics and Genomics Biological Solutions Module I
  • MGM 778A: University Program in Genetics and Genomics Biological Solutions Module I
  • MOLCAN 818: Molecular Mechanisms of Oncogenesis
  • PHARM 393: Research Independent Study
  • PHARM 394: Research Independent Study
  • PHARM 493: Research Independent Study
  • PHARM 494: Research Independent Study
  • PHARM 495: Research Independent Study
  • PHARM 818: Molecular Mechanisms of Oncogenesis
  • UPGEN 778A: University Program in Genetics and Genomics Biological Solutions Module I

In the News

Representative Publications

  • Joh, DY; Heggestad, JT; Zhang, S; Anderson, GR; Bhattacharyya, J; Wardell, SE; Wall, SA; Cheng, AB; Albarghouthi, F; Liu, J; Oshima, S; Hucknall, AM; Hyslop, T; Hall, AHS; Wood, KC; Shelley Hwang, E; Strickland, KC; Wei, Q; Chilkoti, A, Cellphone enabled point-of-care assessment of breast tumor cytology and molecular HER2 expression from fine-needle aspirates., Npj Breast Cancer, vol 7 no. 1 (2021) [10.1038/s41523-021-00290-0] [abs].
  • Su, A; Ling, F; Vaganay, C; Sodaro, G; Benaksas, C; Dal Bello, R; Forget, A; Pardieu, B; Lin, KH; Rutter, JC; Bassil, CF; Fortin, G; Pasanisi, J; Antony-Debré, I; Alexe, G; Benoist, J-F; Pruvost, A; Pikman, Y; Qi, J; Schlageter, M-H; Micol, J-B; Roti, G; Cluzeau, T; Dombret, H; Preudhomme, C; Fenouille, N; Benajiba, L; Golan, HM; Stegmaier, K; Lobry, C; Wood, KC; Itzykson, R; Puissant, A, The Folate Cycle Enzyme MTHFR Is a Critical Regulator of Cell Response to MYC-Targeting Therapies., Cancer Discov, vol 10 no. 12 (2020), pp. 1894-1911 [10.1158/2159-8290.CD-19-0970] [abs].
  • Vaseva, AV; Bandyopadhyay, A; Del Pozo, V; Goodwin, CM; Gautam, P; Wennerberg, K; Wood, KC; Chen, Y; Der, CJ; Houghton, PJ, Parallel targeting of RAF/MEK/ERK pathway in RAS-mutant embryonal rhabdomyosarcoma, Cancer Research, vol 80 no. 14 (2020), pp. 72-72 [abs].
  • Ozkan-Dagliyan, I; Diehl, JN; George, SD; Schaefer, A; Papke, B; Klotz-Noack, K; Waters, AM; Goodwin, CM; Gautam, P; Pierobon, M; Peng, S; Gilbert, TSK; Lin, KH; Dagliyan, O; Wennerberg, K; Petricoin, EF; Tran, NL; Bhagwat, SV; Tiu, RV; Peng, S-B; Herring, LE; Graves, LM; Sers, C; Wood, KC; Cox, AD; Der, CJ, Low-Dose Vertical Inhibition of the RAF-MEK-ERK Cascade Causes Apoptotic Death of KRAS Mutant Cancers., Cell Reports, vol 31 no. 11 (2020) [10.1016/j.celrep.2020.107764] [abs].
  • Vaseva, AV; Bandyopadhyay, A; Del Pozzo, V; Goodwin, CM; Gautam, P; Wennerberg, K; Wood, KC; Der, CJ; Houghton, PJ, Parallel targeting of RAF/MEK/ERK pathway in RAS-mutant embryonal rhabdomyosarcoma., Molecular Cancer Research : Mcr, vol 18 no. 5 (2020), pp. 59-60 [abs].